AMER SOC HEMATOLOGY

• 

  Publisher Of

  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.  Blood.  128:3083-3100. 2016
  • GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.  Blood.  127:2723-2731. 2016
  • Cerebral Ischemia in Adults with Sickle Cell Disease after First Stroke.  Blood.  124. 2014
  • Health-Related Quality of Life in Children with Sickle Cell Disease: Impact of Blood Transfusion Therapy.  Blood.  124. 2014
  • Impact of Comorbidities on Length of Stay and Mortality in Hospitalized Patients with Cancer and Febrile Neutropenia.  Blood.  124. 2014
  • MEK Inhibitors, Novel Anti-Adhesive Molecules, Reverse Sickle Red Blood Cell Adhesion and Vaso-Occlusion in Vivo.  Blood.  124. 2014
  • Patent Foramen Ovale in Adult Patients with Sickle Cell Disease and Stroke.  Blood.  124. 2014
  • Prognostic Disclosure in Acute Myeloid Leukemia (AML): A Qualitative Study of Patient Preferences and Physician Practices.  Blood.  124. 2014
  • The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia.  Blood.  124. 2014
  • The Use of Chronic Transfusions in Sickle Cell Disease for Non-Stroke Related Indications.  Blood.  124. 2014
  • Venous Thromboembolism (VTE) Surveillance: Incidence, Characteristics, and Initial Treatment of VTE Patients.  Blood.  124. 2014
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.  Blood.  124:1915-1925. 2014
  • A Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme (R) Infusions Every 4 Weeks Versus Every 2 Weeks in the Maintenance Therapy of Patients with Type 1 Gaucher Disease.  Blood.  112:460-460. 2008
  • A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies..  Blood.  112:350-350. 2008
  • Adherence with Hydroxyurea in Children with Sickle Cell Disease.  Blood.  112:69-69. 2008
  • Antecedent Transfusion and Primary Hemorrhagic Stroke in Adults with Sickle Cell Disease..  Blood.  112:512-512. 2008
  • Apolipoprotein E-Mimetic Therapeutic Peptides Mediate CLL Cell Cytotoxicity.  Blood.  112:140-140. 2008
  • Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.  Blood.  112:1142-1142. 2008
  • Complications of Hysterectomy in Women with Von Willebrand Disease.  Blood.  112:1166-1166. 2008
  • Development of mPF4/Heparin Antibodies in a Murine Platelet Activation Model.  Blood.  112:106-107. 2008
  • Differential Impact of Inhibitory and Activating Killer Ig-Like Receptors and HLA Ligand on Outcomes of Transplantation for Myeloid and Lymphoid Malignancies.  Blood.  112:1118-1118. 2008
  • Does Living Closer to a Medical Care Center Matter in Sickle Cell Disease?.  Blood.  112:323-324. 2008
  • Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.  Blood.  112:760-760. 2008
  • Encoraging Results after Alternative Donor Transplantation for Myelodysplastic Syndrome.  Blood.  112:685-686. 2008
  • Erythrocyte Adhesion and Phosphatidylserine Exposure in HbSC Disease: Baseline Data from the CHAMPS Study..  Blood.  112:861-861. 2008
  • Functional and Biochemical Changes in Stored Human Red Blood Cells.  Blood.  112:1355-1355. 2008
  • Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.  Blood.  112:785-786. 2008
  • Genomic Approaches to Identifying Risk for Pulmonary Artery Hypertension among Individuals with Sickle Cell Disease..  Blood.  112:514-514. 2008
  • Identification of Therapeutic Targets for Chronic Lymphocytic Leukemia in the Relapsed and Refractory Setting.  Blood.  112:720-720. 2008
  • Increased Hepcidin Expression in Mice Affected by beta-Thalassemia Reduces Iron Overload with No Effect on Anemia.  Blood.  112:53-53. 2008
  • Isolation and Expansion of Oligodendrocytes from Thawed, Cryopreserved Human Umblilical Cord Blood.  Blood.  112:1193-1193. 2008
  • MicroRNAs Distinguish Burkitt Lymphoma from the Molecular Subsets of Diffuse Large B Cell Lymphoma.  Blood.  112:1151-1151. 2008
  • MicroRNAs Regulate Mature B Cell Differentiation.  Blood.  112:262-262. 2008
  • Monocytes Are a Particularly Favorable Target for Surface Platelet Factor 4 (PF4) Antigenic Complex Formation in Heparin-Induced Thrombocytopenia: New Insights into the Thrombotic Risk in HIT.  Blood.  112:107-107. 2008
  • Obstetric and Gynecological History in Sickle Cell Disease Females.  Blood.  112:867-868. 2008
  • Plasmacytoid CD123+Dendritic Cell Recovery Is An Independent Predictor of Survival after Unrelated Cord Blood Transplant (UCBT).  Blood.  112:777-777. 2008
  • Prolonged Survival despite High Disease Burden in Elderly (>= 55) Patients with Hb SS or Hb S beta 0 Thalassemia.  Blood.  112:264-264. 2008
  • Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation.  Blood.  112:133-134. 2008
  • Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML.  Blood.  112:1019-1020. 2008
  • Risk factors for primary hemorrhagic stroke in adults with sickle cell disease.  Blood.  110:19B-20B. 2007
  • Bleeding.Events and other complications during pregnancy and childbirth in women with Von Willebrand disease..  Blood.  108:302A-302A. 2006
  • Blocking adhesion of sickle erythrocytes to endothelial alpha V beta 3 using RNA aptamer..  Blood.  108:206A-207A. 2006
  • Genetic polymorphisms associated with priapism in sickle cell disease..  Blood.  108:236A-237A. 2006
  • Role of A91V mutation in perforin gene in hemophagocytic lymphohistiocytosis.  Blood.  104:1910-1910. 2004
  • Absolute lymphoid and myeloid dendritic cell counts in umbilical cord blood, bone marrow, and peripheral blood..  Blood.  98:321B-321B. 2001
  • Alemtuzumab (Campath) in relapsed or refractory CLL or PLL..  Blood.  98:290B-291B. 2001
  • Binding and uptake of PF4/heparin/antibody complexes in multiple cell types..  Blood.  98:35A-35A. 2001
  • Cord blood donor pre-screening: Impact of exclusion criteria on minority recruitment..  Blood.  98:104B-104B. 2001
  • Correction of Hurler Syndrome with unrelated umbilical cord blood transplantation..  Blood.  98:667A-667A. 2001
  • Cytokine modulation of inducible nitric oxide synthase (NOS2) mRNA levels and apoptosis in B-cell chronic lymphocytic leukemia (B-CLL): A quantitative analysis..  Blood.  98:362A-362A. 2001
  • Dose dense, high intensity therapy for mantle cell lymphoma..  Blood.  98:681A-682A. 2001
  • Durable engraftment of mismatched unrelated cord blood following a non-myeloablative preparative regimen for adults..  Blood.  98:185A-185A. 2001
  • Enrichment of donor erythroid cells after non-myeloablative bone marrow transplantation (BMT) for sickle cell anemia (SCA)..  Blood.  98:490A-490A. 2001
  • Flow cytometric analysis in two large cohorts of patients with PNH..  Blood.  98:221A-221A. 2001
  • Functional T cell immunity before myeloid engraftment by donor post-thymic T cells in pediatric unrelated cord blood transplant recipients..  Blood.  98:379A-379A. 2001
  • High-dose immunosuppressive therapy (HDIT) for severe systemic sclerosis (SSc)..  Blood.  98:395B-395B. 2001
  • Impaired anticoagulant response to thrombin improves after regression of atherosclerosis in monkeys..  Blood.  98:257A-257A. 2001
  • Increased microvessel density in non-Hodgkin's lymphoma (NHL) is localized to the site of disease changes in accordance with disease response..  Blood.  98:236B-236B. 2001
  • J82 cell inositol polyphosphatide signaling via factor Xa and factor VIIa: The possible role of protease-activated receptor 2 (PAR-2) activation..  Blood.  98:53B-53B. 2001
  • Lack of standardization of methodology for enumeration of CD34 in banked umbilical cord blood..  Blood.  98:333B-333B. 2001
  • Low dose, weekly, paclitaxel as salvage therapy for non-Hodgkins lymphoma (NHL)..  Blood.  98:246B-246B. 2001
  • MRD allo transplantation using a large volume leukopheresis product mobilized with G-CSF and Decadron, pharmacokinetics directed modest dose intravenous busulfan plus fludarabine conditioning, and long MTX/CSA results in sustained engraftment, low 30 day mortality, and low incidence of severe GVHD..  Blood.  98:200A-200A. 2001
  • Molecular evidence of engraftment in bone marrow after nonmyeloablative allogeneic stem cell transplant (NMASCT) is an unreliable indicator of residual/recurrent disease in the marrow..  Blood.  98:185A-185A. 2001
  • Molecular interaction of the Fanconi Anemia (FA) and Ataxia Telangiectasia (AT) pathways..  Blood.  98:782A-782A. 2001
  • Multi-institutional phase II, randomized dose finding study of defibrotide (DF) in patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Promising response rate without significant toxicity in a high risk population..  Blood.  98:853A-853A. 2001
  • Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells..  Blood.  98:420A-421A. 2001
  • Non-myeloablative transplantation using CAMPATH 1H for T depletion of mismatched, related donor peripheral blood stem cells..  Blood.  98:669A-669A. 2001
  • Phase I trial of prolonged infusion gemcitabine with fludarabine for relapsed/refractory acute leukemia..  Blood.  98:220B-221B. 2001
  • Prolonged infusion gemcitabine in combination with CPT-11 for relapsed or refractory hematologic malignancies..  Blood.  98:209B-209B. 2001
  • Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma (NHL)..  Blood.  98:247B-247B. 2001
  • Reconstitution of T cell and dendritic cell immunity 50 days post unrelated cord blood transplant predicts the incidence of opportunistic infections and acute GVHD in children..  Blood.  98:204A-204A. 2001
  • Red cell signaling pathways cause increased sickle cell adhesion to non-activated endothelial cells..  Blood.  98:484A-484A. 2001
  • Regulation of T and NK cell mediated cytotoxicity by the CD7 ligand, k12..  Blood.  98:23A-23A. 2001
  • Sickle red cell B-CAM/LU mediates adhesion to multiple sites of laminin under different conditions..  Blood.  98:484A-485A. 2001
  • The clinical course of PNH in the USA and in Japan..  Blood.  98:220A-220A. 2001
  • Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT)..  Blood.  98:687A-687A. 2001
  • alpha-adducin connects actin filament barbed ends to the platelet membrane skeleton..  Blood.  98:787A-787A. 2001
  • Assay method, cord blood bank, nucleated cell count, and neonatal factors influence the CD34+cell count in cord blood: The COBLT experience..  Blood.  96:302B-302B. 2000
  • Banked umbilical cord blood is an excellent source of donor hematopoietic stem cells for infants with malignant and non-malignant conditions lacking a related donor..  Blood.  96:587A-+. 2000
  • Binding and activation of monocytes by PF4/heparin specific antibodies..  Blood.  96:269A-269A. 2000
  • Characterization of HLA polymorphism in an ethnically diverse cord blood bank..  Blood.  96:301B-301B. 2000
  • Cytokine regulation of inducible nitric oxide synthase (NOS2) and NOS2 inhibitor-induced apoptosis and death in chronic lymphocytic leukemia cells..  Blood.  96:159A-159A. 2000
  • Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after high-dose immunosuppressive therapy (HDIT) and autologous CD34-selected stem cell transplantation (SCT) for severe autoimmune diseases..  Blood.  96:406A-406A. 2000
  • Hematopoietic engraftment and survival after unrelated donor umbilical cord blood (UCB) transplantation in adult recipients..  Blood.  96:587A-+. 2000
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model demonstrates the requirement for human platelet factor 4 and platelet activation through Fc gamma RIIA..  Blood.  96:221A-221A. 2000
  • High dose chemotherapy followed by transplantation of unrelated, banked, umbilical cord blood provides curative therapy for young pediatric patients with familial erythrophagocytic lymphohistiocytosis (FEL)..  Blood.  96:362B-362B. 2000
  • High-dose immunosuppressive therapy (HDIT) and autologous stem cell transplant for severe systemic sclerosis (SSc)..  Blood.  96:844A-844A. 2000
  • Human erythrocyte and endothelial cells contain tissue transglutaminase that can regulates inflammation and platelet function by binding and releasing nitric oxide..  Blood.  96:38A-38A. 2000
  • In vivo behavior of factor IX and certain GLA domain mutants evaluated in coagulation factor M-deficient mice..  Blood.  96:35A-35A. 2000
  • Inhibition of tyrosine kinase activity by SUGEN 5416 inhibits fibrin dependent angiogenesis..  Blood.  96:57B-57B. 2000
  • Inverse relationship of plasma prostaglandin-E-2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria..  Blood.  96:31B-31B. 2000
  • Limitations of using CD23 expression by flow cytometry to differentiate mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma..  Blood.  96:330A-330A. 2000
  • Low incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV-PTLD) in 263 unrelated donor umbilical cord blood transplant recipients..  Blood.  96:206A-206A. 2000
  • Nitric oxide as a nonprotein regulator of hematopoietic cell proliferation and differentiation-relationship to malarial anemia..  Blood.  96:14B-14B. 2000
  • Outcomes of unrelated umbilical cord blood transplantation in 158 pediatric patients consecutively transplanted at a single institution using cord blood units from a single bank..  Blood.  96:206A-206A. 2000
  • Overexpression of anti-apoptosis genes in association with resistance to apoptosis observed in bone marrow failure syndromes..  Blood.  96:526A-526A. 2000
  • Oxygen-dependent export of nitric oxide from red blood cells..  Blood.  96:596A-+. 2000
  • Pediatric ALK-positive lymphomas coexpress c-Myc..  Blood.  96:128A-128A. 2000
  • Phase I trial of continuously infused gemcitabine with CPT-11 for refractory hematologic malignancies..  Blood.  96:216B-216B. 2000
  • Phase I trial of continuously infused gemcitabine with mitoxantrone for high risk or relapsed acute leukemia..  Blood.  96:326A-326A. 2000
  • Phase I trial of escalting doses of 4-hydroxycyclophosphamide (4HC) purged autologous peripheral blood progenitor cells (PBPC) for leukemia..  Blood.  96:385A-385A. 2000
  • Predictive value of day+50 immune reconstitution on the incidence of opportunistic infections and acute GVHD following unrelated cord blood transplants in children..  Blood.  96:789A-789A. 2000
  • Preliminary characterization of the surface staining of placental derived adherent cells: A potential new source of stroma for umbilical cord blood (UCB) expansion..  Blood.  96:150B-150B. 2000
  • Relationship between transferrin saturation and iron stores in US African-American and Caucasian populations..  Blood.  96:226A-226A. 2000
  • Serum alpha-2 macroglobulin (alpha 2M) determines NAT binding capacity in patients with peripheral vascular disease (PVD)..  Blood.  96:273A-273A. 2000
  • Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT)..  Blood.  96:842A-843A. 2000
  • Umbilical cord blood graft engineering using bone marrow stroma to enhance hematopoietic stem and progenitor cell content..  Blood.  96:774A-774A. 2000
  • Unrelated umbilical cord blood transplant for osteopetrosis..  Blood.  96:207A-207A. 2000
  • Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture..  Blood.  96:754A-754A. 2000
  • A Phase I study of 2-amino-9-B-D-arabinosyl-6-methoxy-9H-purine (506U78) administered on a consecutive five day schedule in children and adults with refractory hematologic malignancies..  Blood.  94:629A-629A. 1999
  • Absolute lymphoid and myeloid dendritic cell counts in umbilical cord blood grafts and in recipients of unrelated umbilical cord blood transplants..  Blood.  94:326B-326B. 1999
  • Acute lymphoblastic leukemia in infancy: Improved outcome with unrelated placental cord blood (PCB) transplants..  Blood.  94:712A-712A. 1999
  • Augmentation of umbilical cord blood (UCB) transplantation with ex vivo expaned cells, a phase I trial using the replicell system..  Blood.  94:571A-571A. 1999
  • Characterization of a monoclonal antibody to PF4/heparin (KKO) with functional and serologic properties of hit antibodies..  Blood.  94:21A-21A. 1999
  • Diffuse alveolar hemorrhage after hematopoietic stem cell transplantation for mucopolysaccharidosis type 6: Report of 3 cases..  Blood.  94:334A-335A. 1999
  • Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients..  Blood.  94:158A-158A. 1999
  • Human platelet adducin: A regulated actin filament barbed end-capping protein..  Blood.  94:216A-216A. 1999
  • Inducible nitric oxide synthase (NOS2) inhibitors induce high level CLL cell apoptosis and death..  Blood.  94:703A-703A. 1999
  • Laminin binding and B-CAM/LU expression by high and low density reticulocytes vs mature red cells in sickle cell disease..  Blood.  94:675A-675A. 1999
  • Manipulation of CD22 signal transduction for the treatment of lymphoma..  Blood.  94:93A-93A. 1999
  • Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with Non-Hodgkin's Lymphoma..  Blood.  94:253B-253B. 1999
  • Stable mixed chimerism after bone marrow transplantation (BMT) for Sickle Cell Disease (SCD)..  Blood.  94:645A-645A. 1999
  • Stroma from adult bone marrow increases the productivity of ex vivo cord blood expansion cultures..  Blood.  94:164B-164B. 1999
  • The effect of cytokine combinations on the clinical scale ex-vivo expansion of umbilical cord blood..  Blood.  94:573A-573A. 1999
  • Transplantation of a patient with congenital neutropenia and invasive fungal disease with unrelated umbilical cord blood using paternal G-CSF mobilized, irradiated granulocyte support..  Blood.  94:368B-369B. 1999
  • Unrelated umbilical cord blood transplants in adult patients (pts) with hematologic malignancies or genetic disorders..  Blood.  94:570A-570A. 1999
  • The oncogenic E2A-HLF fusion protein protects leukemic B-precursor cells from apoptosis..  Blood.  86:1297-1297. 1995
  • SUCCESSFUL TREATMENT (RX) OF PATIENTS (PTS) WITH REFRACTORY SEVERE APLASTIC-ANEMIA (SAA) WITH CONCOMITANT CYCLOSPORINE (CSA) AND COLONY-STIMULATING FACTORS (CSF).  Blood.  84:A10-A10. 1994
  • Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival ("Potential Cure") over the Past Four Decades: Analysis of SWOG Trial Data.  Blood. 2017
  • Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based Survey.  Blood. 2017
  • Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia.  Blood. 2017
  • Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP.  Blood. 2017
  • Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment.  Blood. 2017
  • Evaluation of Residual Disease Positivity Rates in Adult Acute Lymphoblastic Leukemia Patients Treated with Asparaginase Versus Non-Asparaginase Containing Regimens.  Blood. 2017
  • Favorable Outcomes with Fludarabine, High Dose Cytarabine and Granulocyte Colony Stimulating Factor (FLAG) As Re-Induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow.  Blood. 2017
  • Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs.  Blood. 2017
  • IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia.  Blood. 2017
  • Insurance Design and Out-of-Pocket (OOP) Costs: a Comparison of Oral and Intravenous (IV) Treatment Plans for Chronic Lymphocytic Leukemia (CLL) in the Era of the Affordable Care Act (ACA).  Blood. 2017
  • Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study.  Blood. 2017
  • Multiple Myeloma Symptom Burden, Perceived Control, and Quality of Life: Findings from the Cancer Experience Registry.  Blood. 2017
  • PD-L1 Expression and Gene Amplification in CD30+Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics.  Blood. 2017
  • Patient-Reported Distress in Hodgkin Lymphoma Patients on Active Therapy Vs. Long-Term Survivors.  Blood. 2017
  • Patient-Reported Sleep Quality at Baseline Correlates with 1-Year Survival after Allogeneic Hematopoietic Cell Transplantation in Adults.  Blood. 2017
  • Perceptions of Prognosis and Treatment Risk in Older Patients with Acute Myeloid Leukemia.  Blood. 2017
  • Pre-Transfusion Rejuvenation of RBCs for Red Blood Cell Exchange: Report of Feasibility.  Blood. 2017
  • Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study.  Blood. 2017
  • Quantification of Whole-Brain Oxygenation Extraction Fraction Among People with Sickle Cell Anemia without Stroke History.  Blood. 2017
  • Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib.  Blood. 2017
  • Results from the US Life after Stopping TKIs (LAST) Study.  Blood. 2017
  • Role of Glucose Transporter 1 in Graft-Versus-Host Disease and Graft-Versus-Tumor Effect.  Blood. 2017
  • The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation.  Blood. 2017
  • The Timing and Epidemiology of Enterococcus Faecium and E. Faecalis Bloodstream Infections (BSI) in Patients with Acute Leukemia Receiving Chemotherapy.  Blood. 2017
  • Transcript Expression, Intron Retention, and RNA Editing Are Conserved in Human Platelets over a 4 Year Period.  Blood. 2017
  • Transfusion Dependence and Use of Hospice Among Medicare Beneficiaries with Leukemia.  Blood. 2017
  • Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Real-World US Practices.  Blood. 2017
  • Cell-Free DNA Is Elevated after Acute Arterial Injury in Infants.  Blood. 2016
  • Three Factor Prothrombin Complex Concentrates in Cardiac Surgery: A Novel Algorithmic Approach to Perioperative Bleeding.  Blood. 2016
  • A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma.  Blood. 2015
  • A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition.  Blood. 2015
  • A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML).  Blood. 2015
  • A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies.  Blood. 2015
  • AAV Gene Therapy for MPS1 Corneal Clouding and Joint Stiffness.  Blood. 2015
  • Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.  Blood. 2015
  • Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study.  Blood. 2015
  • Autologous Cord Blood Infusion for the Treatment of Brain Injury in Children with Cerebral Palsy.  Blood. 2015
  • Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival.  Blood. 2015
  • Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study.  Blood. 2015
  • Clinical Outcomes of Patients with Newly Diagnosed Multiple Myeloma Receiving Triplet Therapy in the Connect MM (R) Disease Registry.  Blood. 2015
  • Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study.  Blood. 2015
  • Cord Blood Unit Cryopreservation: Positioning Segments for Potency Assessment.  Blood. 2015
  • Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial.  Blood. 2015
  • Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106.  Blood. 2015
  • Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma.  Blood. 2015
  • Dickkopf 1 (Dkk1) Regulates Hematopoietic Stem Cell Regeneration.  Blood. 2015
  • ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP).  Blood. 2015
  • Early Allogeneic Stem Cell Transplantation and Use of Asparaginase during Induction Chemotherapy Appear to Improve Otherwise Poor Outcomes in Adult T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) Patients: A Multi Institutional Review.  Blood. 2015
  • Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia.  Blood. 2015
  • Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches.  Blood. 2015
  • Genome-Wide Evaluation of Epistasis with APOL1 Risk Variants in Sickle Cell Disease Nephropathy.  Blood. 2015
  • Growth Factor Receptor-Bound Protein 10 (Grb10) Regulates Hematopoietic Stem Cell (HSC) Self-Renewal Via Control of mTOR Signaling.  Blood. 2015
  • Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone.  Blood. 2015
  • Impact of Available Therapies on Survival of Very Elderly Myelodysplastic Syndrome (MDS) Patients (Age above 75 yrs).  Blood. 2015
  • Impact of GvHD and Other Patient-, Disease-, Donor and Transplantation-Related Factors on 5 Year Relapse after Unrelated Cord Blood Transplantation for Children with Acute Lymphoblastic Leukemia in Remission.  Blood. 2015
  • Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML).  Blood. 2015
  • Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML).  Blood. 2015
  • Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants.  Blood. 2015
  • North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia.  Blood. 2015
  • Outcomes for Older Patients with Acute Myeloid Leukemia Admitted to the Intensive Care Unit.  Blood. 2015
  • Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM).  Blood. 2015
  • Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML).  Blood. 2015
  • Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials.  Blood. 2015
  • Prothrombin Complex Concentrates and Cardiac Surgery.  Blood. 2015
  • Rapid Achievement of MR4.5 after Switching from Imatinib (IM) to Nilotinib (NIL) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Preliminary Results from ENESTgoal.  Blood. 2015
  • Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306.  Blood. 2015
  • Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia.  Blood. 2015
  • SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML.  Blood. 2015
  • Symptom Burden, Quality of Life, and Distress in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy: Results of a Prospective Electronic Patient-Reported Outcomes Study.  Blood. 2015
  • TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia.  Blood. 2015
  • Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD).  Blood. 2015
  • The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status.  Blood. 2015
  • The Thrombotic Microangiopathy Registry of North America.  Blood. 2015
  • Thrombocytopenia in Hospitalized Non-ICU Patients.  Blood. 2015
  • beta-arrestin2 Is Necessary for Development of MPLW515L Mutant Primary Myelofibrosis.  Blood. 2015
  • A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis.  Blood. 2014
  • A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma.  Blood. 2014
  • A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis.  Blood. 2014
  • A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117.  Blood. 2014
  • Acute and Chronic Lymphocytic Leukemia Induces Exhaustion and Suppresses Metabolic Reprogramming in T Cell Activation.  Blood. 2014
  • Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2014
  • An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma.  Blood. 2014
  • Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT).  Blood. 2014
  • Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization By Patients with Sickle Cell Disease.  Blood. 2014
  • Broncho-Alveolar Lavage and Lung Biopsy in Patients with Hematological Malignancy and Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review and Meta-Analysis.  Blood. 2014
  • Calcium Calmodulin Dependent Kinase Kinase 2 Regulates Hematopoietic Stem Cell Regeneration and Quiescence.  Blood. 2014
  • Clinical and Biological Features of Primary Testicular B-Cell Lymphoma - a Single-Institution Study of 89 Cases.  Blood. 2014
  • Clinician Approaches to Myeloma in Academia and the Community : An in-Practice Qualitative Study.  Blood. 2014
  • Connect MM (R) the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM).  Blood. 2014
  • Connect MM (R) the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease.  Blood. 2014
  • Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update.  Blood. 2014
  • Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.  Blood. 2014
  • Defining Immunoglobulin Somatic Hypermutation in De Novo Diffuse Large B-Cell Lymphoma Patients: Potential Application for Prognosis and Risk Stratification.  Blood. 2014
  • Double IGHV Gene Rearrangements in Chronic Lymphocytic Leukemia.  Blood. 2014
  • Effects of Sulforaphane Obtained from Broccoli Sprout Homogenate in Patients with Sickle Cell Disease (SCD).  Blood. 2014
  • Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG.  Blood. 2014
  • Epigenetics of Cellular Memory: Insights from the Chromatin Accessibility Landscape of the Mitotic Genome.  Blood. 2014
  • Evidence for a Dominant Negative Effect Conferred By the APOL1 G2 Sickle Cell Nephropathy Risk Allele in an in Vivo Model.  Blood. 2014
  • Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL).  Blood. 2014
  • Genes Associated with Alloimmunization to Blood Group Antigens in Sickle Cell Disease.  Blood. 2014
  • Genes Associated with Survival in Adult Sickle Cell Disease.  Blood. 2014
  • Genome-Wide Association Study of Glomerular Filtration Rate in a Cohort of Sickle Cell Disease Patients.  Blood. 2014
  • Growing Pains - Determination of Transfer and Transition from Pediatrics to Adult Outpatient Clinics for Patients with Sickle Cell Disease (SCD).  Blood. 2014
  • Growth Factor Receptor-Bound Protein 10 (Grb10) Regulates Hematopoietic Stem Cell Renewal.  Blood. 2014
  • Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR).  Blood. 2014
  • Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML).  Blood. 2014
  • Laboratory Assessment of Anti-Coagulant Properties of a Von Willebrand Factor Targeted Aptamer.  Blood. 2014
  • NF-kappa B Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2014
  • Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL).  Blood. 2014
  • Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial.  Blood. 2014
  • Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma.  Blood. 2014
  • Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience.  Blood. 2014
  • Primary Treatment of Invasive Mucormycosis (IM) with Isavuconazole (VITAL Study) or Amphotericin Formulations (FungiScope (TM)): Case Matched Analysis.  Blood. 2014
  • Protein Tyrosine Phosphatase-Sigma (PTP sigma) Regulates Hematopoietic Stem Cell Repopulating Capacity.  Blood. 2014
  • Understanding the Underlying Immune Response in HIT: Uptake of PF4/Heparin Complexes By Monocytes & Dendritic Cells.  Blood. 2014
  • X-Ray Structure of an Anticoagulant RNA Aptamer Bound to Factor Xa. Structural Basis for Its Ability to Disrupt Interactions Between Xa and Va within Prothrombinase.  Blood. 2014
  • Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance).  Blood. 3903-3906. 2013
  • MYC Mutation Profiling In 708 De Novo Diffuse Large B-Cell Lymphoma Demonstrates That Genetic Abnormalities In The Coding Sequence and Untranslated Regions Have Different Prognostic and Clinical Significance: A Report From The International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2013
  • NIH and National Foundation Expenditures For Sickle Cell Disease and Cystic Fibrosis Are Associated With Pubmed Publications and FDA Approvals.  Blood. 2013
  • STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report Fro The International DLBCL Rituximab-CHOP Consortium Program.  Blood. 2013
  • A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502.  Blood. 2012
  • Genetic Loss of Tmprss6 Increases Effective Erythropoiesis in a Mouse Model of beta-Thalassemia.  Blood. 2012
  • Modeling Variation in the Human Lymphoma Microenvironment with the E mu-Myc Mouse Model.  Blood. 2012
  • No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial.  Blood. 2012
  • Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation.  Blood. 2012
  • Therapeutic Benefit of Small Molecule Inhibitors of MEK/ERK in Reducing Sickle Red Cell Adhesion and Vaso-Occlusion in Vivo.  Blood. 2012
  • A Common Deletion Polymorphism in the BIM Gene Contributes to Intrinsic Imatinib Resistance in Chronic Myelogenous Leukemia.  Blood. 724-724. 2011
  • A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes.  Blood. 231-232. 2011
  • A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response.  Blood. 666-667. 2011
  • ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet 'Favorable' Genetic Category.  Blood. 192-192. 2011
  • An Elevated Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease Is Associated with Polymorphisms in Genes Impacting Innate Immunity.  Blood. 240-240. 2011
  • Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease.  Blood. 931-932. 2011
  • CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report.  Blood. 116-116. 2011
  • Characterization of Pim Protein Kinases and Evaluation of Small Molecule Inhibitors in Multiple Myeloma.  Blood. 1254-1255. 2011
  • Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost.  Blood. 1729-1729. 2011
  • Chronic Lymphocytic Leukemia Shares a Common Cellular Origin with Regulatory B10 Cells.  Blood. 132-133. 2011
  • Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol.  Blood. 226-227. 2011
  • Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends.  Blood. 839-840. 2011
  • Genomic Heterogeneity in B-Cell Malignancies.  Blood. 1480-1480. 2011
  • HIT Antibody Seropositivity and Thromboembolic Events After Cardiac Surgery.  Blood. 524-525. 2011
  • High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma.  Blood. 1152-1152. 2011
  • High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation.  Blood. 879-879. 2011
  • Hijacking the Niche: The Role of Stromal Osteopontin in the Induction of Leukemic Dormancy within the Bone Marrow Microenvironment.  Blood. 342-343. 2011
  • Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma.  Blood. 1765-1765. 2011
  • Inflammatory Polymorphisms Link the Risk of Acute Chest Syndrome with Asthma in Adults with Sickle Cell Disease.  Blood. 493-493. 2011
  • MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML).  Blood. 635-635. 2011
  • Personalizing Cancer Supportive Care: Predicting Neutropenic Complications in Patients Receiving Intermediate Risk Cancer Chemotherapy.  Blood. 469-469. 2011
  • Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2).  Blood. 370-371. 2011
  • Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures.  Blood. 1476-1477. 2011
  • Prevalence of MBL Increases Over Time In Relatives of CLL Families.  Blood. 1659-1659. 2011
  • Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG.  Blood. 1080-1080. 2011
  • Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts).  Blood. 190-191. 2011
  • Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia.  Blood. 778-779. 2011
  • Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia.  Blood. 1532-1533. 2011
  • Referral Patterns and Outcomes for Women with for Recurrent Pregnancy Loss Managed At a Multidisciplinary Thrombosis Program.  Blood. 1792-1793. 2011
  • Relationships Among Commonly Used Measures of Cord Blood Potency, ALDH(br) Cell Content, and Colony Forming Cell Content in Cord Blood Units Prior to Cryopreservation: Towards An Improved Metric for Potency of Banked Cord Blood.  Blood. 1731-1732. 2011
  • Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia.  Blood. 348-348. 2011
  • Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia-Preliminary Results From a Phase I Study.  Blood. 39-40. 2011
  • Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients.  Blood. 1125-1125. 2011
  • Sirolimus Inhibits Proliferation but Enhances Suppressive Activity of Rhesus Macaque Natural CD4 Regulatory T Cells.  Blood. 461-461. 2011
  • Tandem HLA-Mismatched Cadaveric Unrelated Donor Lung Transplant Followed by CD3-and CD19-Depleted Bone Marrow Transplant From the Same Donor Permits Withdrawal of Systemic Immunosuppression with Graft Acceptance and Functional Immune Reconstitution.  Blood. 460-461. 2011
  • The Impact of Factor IX Level on Thrombin Generation and Bleeding During Warfarin Anticoagulation.  Blood. 250-250. 2011
  • The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation.  Blood. 1736-1736. 2011
  • The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcome.  Blood. 1229-1229. 2011
  • The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study.  Blood. 433-434. 2011
  • Transient Decrease in Factor VIII Following Delivery: Clearance or Consumption?.  Blood. 992-993. 2011
  • Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage.  Blood. 1361-1362. 2011
  • Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study.  Blood. 1705-1706. 2011
  • What Clinical Characteristics of Mothers and Babies Favorably Influence Cord Blood Potency? Defining Parameters That Can Guide Public Cord Blood Collection.  Blood. 225-226. 2011
  • Whole Genome and Exome Sequencing Reveals the Genetic Landscape of Burkitt Lymphoma.  Blood. 199-200. 2011
  • Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm.  Blood. 552-552. 2011
  • A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study.  Blood. 1636-1636. 2010
  • A Comprehensive Comparison Immune Recovery In Adult Patients Following Allogeneic Umbilical Cord Blood, Matched Sibling and Matched Unrelated Donor Stem Cell Transplantation.  Blood. 954-955. 2010
  • A Novel Scoring System, the Cord Blood Apgar, Predicts Engraftment After Cord Blood Transplantation: Optimization of Selection of Cord Blood Units (CBUs) for Transplantation.  Blood. 158-158. 2010
  • A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies.  Blood. 1349-1350. 2010
  • A Randomized Trial of the Safety and Benefit of Transfusion Vs. Standard Care In the Prevention of Sickle Cell-Related Complications In Adults: a Preliminary Report From the Phase II NHLBI Comprehensive Sickle Cell Centers (CSCC) Study of Neuropsychological Dysfunction and Neuroimaging Abnormalities In Neurologically Intact Adult Patients with Sickle Cell Disease.  Blood. 1321-1321. 2010
  • A Retrospective Multi-Center Analysis of Prognostic Factors Determining Outcomes In Patients with Secondary AML..  Blood. 883-884. 2010
  • ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.  Blood. 9-10. 2010
  • Allogeneic Effector Memory T Cells Enhance Hematopoietic Engraftment and Immune Reconstitution After Stem Cell Transplantation.  Blood. 41-41. 2010
  • Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma.  Blood. 351-352. 2010
  • An Ear-Tissue Model for High-Resolution In Vivo Imaging..  Blood. 623-623. 2010
  • Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study.  Blood. 237-238. 2010
  • Anti-Inflammatory Markers Are Associated with Glomerular Filtration Rate In Adults with Sickle Cell Disease.  Blood. 693-694. 2010
  • Atypical Activation of Plasma Membrane-Bound ERK1/2 Is Associated with Regulation of Sickle Red Cell Adhesion to Endothelium.  Blood. 122-122. 2010
  • Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) In Children and Adolescents with Acute Leukemia.  Blood. 98-99. 2010
  • Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol.  Blood. 399-400. 2010
  • Dendritic Cell Activation by PF4/H Multimolecular Complexes.  Blood. 318-319. 2010
  • Disruption of PF4/Hep Multimolecular Complex Assembly Using a Minimally Anticoagulant Heparin (ODSH).  Blood. 319-319. 2010
  • Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.  Blood. 1423-1424. 2010
  • Efficacy and Safety of Hematopoietic Stem Cell Remobilization with Plerixafor (Mozobil (R)) plus G-CSF In Adult Patients with Non-Hematologic Malignancies..  Blood. 925-925. 2010
  • Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt - Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002.  Blood. 374-375. 2010
  • Efficacy of Denileukin Diftitox Retreatment In Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response.  Blood. 1179-1179. 2010
  • Facilitation of Hematopoietic Reconstitution Via Inhibition of Bone Marrow Endothelial Cell-Mediated SDF-1 Signaling.  Blood. 1578-1578. 2010
  • Factors Associated with Heterocellular Aggregate Formation In Sickle Cell Disease..  Blood. 1101-1101. 2010
  • GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease..  Blood. 685-686. 2010
  • Genetic Variation In MYH9 Is Associated with Sickle Cell Disease Nephropathy.  Blood. 692-692. 2010
  • Heparin Modifies the Immunogenicity of Positively-Charged Proteins.  Blood. 615-616. 2010
  • Hepcidin as a Therapeutic Tool to Limit Iron Overload and Improve Anemia In beta-Thalassemia.  Blood. 443-444. 2010
  • Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA).  Blood. 123-124. 2010
  • Identification of Thrombospondin-1 and L-Selectin as Potential Plasma Biomarkers of Silent Cerebral Infarct In Children with Sickle Cell Disease Using a Proteomic-Based Approach.  Blood. 119-119. 2010
  • Identification of a Costimulation Blockade Resistant Mechanism of Bone Marrow Allograft Rejection Induced by Infection with a Murine EBV Homologue..  Blood. 625-625. 2010
  • Increased Platelet Binding of NN1731, a Factor VIIa Variant with Enhanced Tissue Factor-Independent Activity.  Blood. 491-491. 2010
  • Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes.  Blood. 1100-1100. 2010
  • Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci.  Blood. 1014-1014. 2010
  • Long-Term Follow-up of Adults with Severe Sickle Cell Disease After Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning.  Blood. 120-120. 2010
  • Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).  Blood. 1430-1431. 2010
  • Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study.  Blood. 48-49. 2010
  • Overall Survival of Lymphoma Patients In Randomized Controlled Trials Comparing Primary G-CSF Chemotherapy Support to Control.  Blood. 639-640. 2010
  • Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.  Blood. 1168-1169. 2010
  • Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS.  Blood. 1351-1351. 2010
  • Pleiotrophin Signaling Is Necessary and Sufficient for Hematopoietic Stem Cell Self-Renewal In Vivo.  Blood. 180-180. 2010
  • Post-Transplant Lymphoproliferative Disease In Liver Transplant Recipients: A Single Institution Experience.  Blood. 731-731. 2010
  • Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).  Blood. 768-769. 2010
  • Pregnancy In Type 1 Von Willebrand Disease: A Prospective Study of VWF Levels and Risk Factors for Bleeding..  Blood. 606-606. 2010
  • Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905.  Blood. 264-265. 2010
  • Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies..  Blood. 1456-1457. 2010
  • Reduced Intensity Conditioning In Children Undergoing Unrelated Umbilical Cord Blood Transplantation for Non-Malignant Diseases: Preliminary Results Demonstrate a High Rate of Engraftment and Low Incidence of Gvhd..  Blood. 1453-1454. 2010
  • Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation.  Blood. 104-105. 2010
  • Relationship of Soluble Adhesion Receptors to Red Cell Apoptosis In SCD.  Blood. 694-694. 2010
  • Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma.  Blood. 815-816. 2010
  • S-Nitrosylation of Rap1and Relationship to Rap1 Activity and Disease Status In SCD.  Blood. 1098-1098. 2010
  • Six Year, Single Institution, off-Label Use of Recombinant Factor VIIa..  Blood. 603-603. 2010
  • Targeting Destruction of Mcl-1 by Activation of Protein Phosphatase 2A In CLL and B-Cell Lymphomas.  Blood. 1703-1704. 2010
  • The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship.  Blood. 1482-1482. 2010
  • The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study.  Blood. 288-288. 2010
  • The Serine Protease Tmprss6 Regulates Hepcidin Expression, but Its Loss Does Not Cause Systemic Iron Deficiency In the Fetal and Neonatal Periods.  Blood. 1728-1728. 2010
  • Tmprss6, An Inhibitor of Hepatic Bmp/Smad Signaling, Is Required for Hepcidin Suppression and Iron Loading In a Mouse Model of beta-Thalassemia.  Blood. 75-75. 2010
  • Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing-Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.  Blood. 482-483. 2010
  • VE Cadherin Positive Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo.  Blood. 1532-1532. 2010
  • Validation of the Cord Blood (CB) APGAR Score System to Predict Neutrophil Engraftment of Plasma Depleted CB Products.  Blood. 1459-1460. 2010
  • A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.  Blood. 948-949. 2009
  • A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia.  Blood. 918-918. 2009
  • A Phase II Multicentre Study with Elacytarabine as Second Salvage Therapy in Patients with AML..  Blood. 431-431. 2009
  • ALDH(br) Hematopoietic Progenitors Promote Short-Term Engraftment in Experimental Models for Cord Blood Transplantation..  Blood. 960-961. 2009
  • Acute Myeloid Leukemia or Myelodysplastic Syndromes and All-Cause Mortality in Randomized Controlled Trials of Cancer Patients Receiving Chemotherapy with or without Granulocyte Colony-Stimulating Factor: A Systematic Review and Meta-Analysis.  Blood. 1205-1205. 2009
  • Allospecific Effector Memory T Cells Are Able to Mediate Second-Set Skin Graft Rejection but Unable to Induce Graft-Versus-Host Disease.  Blood. 100-100. 2009
  • Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL..  Blood. 1332-1332. 2009
  • Characterization of Receptors Involved in Heparin Antibody Complex Mediated Induction of Tissue Factor Expression in Monocytes.  Blood. 97-98. 2009
  • Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA)..  Blood. 1004-1004. 2009
  • Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.  Blood. 814-814. 2009
  • Creation of a Segment-Based Aldehyde Dehydrogenase Assay as a Biomarker for Cord Blood Potency..  Blood. 1246-1247. 2009
  • Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.  Blood. 272-273. 2009
  • Deletion of Bak and Bax in Tie2+BM Hematopoietic Stem Cells Induces a B Cell Lymphoproliferative Disorder.  Blood. 513-513. 2009
  • Development of a Decision Support Tool to Guide Management of Adults with Sickle Cell Disease: The Emergency Department Sickle Cell Assessment of Strengths and Needs (ED-SCANS)..  Blood. 575-576. 2009
  • Effect of PAI-1 Specific RNA Aptamers On Cell Adhesion and Motility.  Blood. 840-840. 2009
  • Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the "CHAMPS" Trial.  Blood. 338-338. 2009
  • Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.  Blood. 1272-1273. 2009
  • Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.  Blood. 511-511. 2009
  • Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma.  Blood. 728-728. 2009
  • Genome-Wide Analysis of Microdeletions and Identification of NF1 Inactivation in Acute Myelogenous Leukemia..  Blood. 73-74. 2009
  • Genome-Wide Studies in Sickle Cell Anemia Show Associations Between SNPs in the Olfactory Receptor Gene Cluster and Fetal Hemoglobin Concentration.  Blood. 339-339. 2009
  • Heparin Forms Macromolecular Complexes with Protamine and Lysozyme..  Blood. 538-539. 2009
  • Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway.  Blood. 1436-1437. 2009
  • Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm.  Blood. 980-980. 2009
  • Impact of Nucleated Cell Dose On Engraftment and Survival After Unrelated Cord Blood Transplantation for Severe Aplastic Anemia: A Retrospective Study On Behalf of Eurocord and the EBMT SAA WP.  Blood. 1240-1241. 2009
  • Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.  Blood. 866-867. 2009
  • In-Hospital Outcomes Among Sickle Cell Patients with Acute Chest Syndrome: Results From a National Database..  Blood. 557-557. 2009
  • Increased Severity of Pandemic H1N1 Influenza in Children and Young Adults with Sickle Cell Disease.  Blood. 112-112. 2009
  • Influence of Statin Therapy On the Clinical Course of Chronic Lymphocytic Leukemia.  Blood. 926-926. 2009
  • Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.  Blood. 1287-1288. 2009
  • Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).  Blood. 193-193. 2009
  • Low Levels of Apolipoprotein A1 Are Associated with Silent Cerebral Infarets in Children with Sickle Cell Disease.  Blood. 109-110. 2009
  • Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission..  Blood. 425-426. 2009
  • Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.  Blood. 310-311. 2009
  • Molecular Profiling Identifies Plasmablasts as the Cells of Origin of Activated Diffuse Large B Cell Lymphoma.  Blood. 257-257. 2009
  • Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).  Blood. 1277-1277. 2009
  • Overexpression and Phosphorylation of eIF4E Is Required for Beta-Catenin Activation in Blast Crisis Chronic Myelogenous Leukemia.  Blood. 22-22. 2009
  • Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study..  Blood. 457-458. 2009
  • Physiologic Hypoxia Protects Chronic Myelogenous Leukemia Progenitors From Elimination by Imatinib Mesylate.  Blood. 858-858. 2009
  • Plerixafor (Mozobil (R)) Selectively Enhances Donor Hematopoietic Cell Engraftment.  Blood. 155-155. 2009
  • Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)..  Blood. 669-669. 2009
  • Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.  Blood. 326-327. 2009
  • Prevention of Acute GvHD During MHC Haploidentical BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model..  Blood. 968-969. 2009
  • Proteomic-Based Approach for Biomarker Discovery to Predict Silent Cerebral Infarct in Patients with Sickle Cell Disease.  Blood. 1012-1013. 2009
  • Racial Differences in Thrombotic Risk Factors Associated with Adverse Pregnancy Outcome Among Women Obtaining Care in US Thrombosis and Hemostasis Centers.  Blood. 1164-1164. 2009
  • Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.  Blood. 325-326. 2009
  • Retrospective Review of the Natural History of Pulmonary Hypertension in Sickle Cell Disease Demonstrates That Progressive Enlargement of the Left Atrium Is a Strong Predictor of Death..  Blood. 613-614. 2009
  • Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are >= 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors.  Blood. 822-823. 2009
  • The Anti-Inflammatory Investigational Agent LMP-420 Demonstrates in Vitro Cytotoxic Activity against Chronic Lymphocytic Leukemia Cells.  Blood. 931-931. 2009
  • The Complex Relationship Between Sickle Cell Disease and Depression.  Blood. 1014-1015. 2009
  • Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.  Blood. 367-368. 2009
  • Thymic Recovery and De Novo T Cell Production During the First Year After Unrelated Cord Blood Transplant (UCBT) Predicts Overall Survival: A Multivariate Analysis of 93 Patients Following Myeloablative Conditioning and a Single Unit Graft..  Blood. 481-482. 2009
  • Tie2+Bone Marrow Endothelial Cells Regulate Hematopoietic Reconstitution In Vivo.  Blood. 106-106. 2009
  • Tmprss6 Is a Genetic Modifier of the Hfe-Hemochromatosis Phenotype in Mice.  Blood. 259-259. 2009
  • Transplantation Following Myeloablative Cytoreduction Results in Excellent Survival, Long-Term Engraftment, and Donor Chimerism in Children with Chronic Granulomatous Disease Across Donor and Graft Sources.  Blood. 1319-1319. 2009
  • Use of Aldehyde Dehydrogenase Content to Predict Dominating Cord in Double Cord Blood Transplant.  Blood. 847-848. 2009
  • Use of a Computer Based Neurocognitive Software Program in Asymptomatic Neurologically Intact Adults with Sickle Cell Disease..  Blood. 612-612. 2009
  • Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.  Blood. 129-130. 2009
  • Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study.  Blood. 181-181. 2008
  • Comprehensive Ultra High Resolution Analysis of Copy Number and Allele Status Including Novel Microdeletions Spanning NF1 in Acute Myelogenous Leukemia.  Blood. 1066-1066. 2008
  • Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.  Blood. 800-800. 2008
  • Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial..  Blood. 369-370. 2008
  • Final Risk Prediction Model for Neutropenic Complications in Patients Receiving Cancer Chemotherapy.  Blood. 474-475. 2008
  • Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.  Blood. 569-569. 2008
  • Insulin-Like Growth Factor 1 Protects against Lethal Irradiation..  Blood. 1196-1196. 2008
  • Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.  Blood. 749-749. 2008
  • Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy.  Blood. 209-209. 2008
  • Prevention of Acute GvHD during Haplo-BMT: Evaluating the Efficacy of T-Cell Costimulation Blockade Using a Novel Rhesus Macaque Transplant Model.  Blood. 1207-1207. 2008
  • Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II MultiCenter EVOLUTION Study.  Blood. 41-42. 2008
  • Single Donor 4/6 Matched Banked Unrelated Cord Blood Is An Effective Graft Source for Children Undergoing Myeloablative Transplantation for Malignant and Nonmalignant Disorders: Single Center Analysis of 318 Patients.  Blood. 690-690. 2008
  • Standard Versus Dose-Intensified Chemotherapy with Granulocyte Colony-Stimulating Factor for Malignant Lymphoma: Evaluation of Risk for Acute Myeloid Leukemia or Myelodysplastic Syndrome.  Blood. 833-833. 2008
  • Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study.  Blood. 340-341. 2008
  • A conditional risk model for chemotherapy-induced anemia (CIA) in cancer patients..  Blood. 117A-117A. 2007
  • Avoidance of post-thaw wash prior to transplantation of plasma depleted cord blood (PD CB) is associated with improved engraftment & decreased severity of chronic GvHD (cGvHD) without increased relapse.  Blood. 494A-494A. 2007
  • Blocking adhesion of sickle erythrocytes to endothelial P-selectin using an RNAaptamer.  Blood. 51A-51A. 2007
  • Clinical and outcomes findings for thrombotic thrombocytopenic purpura among 467 persons with severely versus not severely deficient ADAMTS13 levels.  Blood. 622A-622A. 2007
  • Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.  Blood. 73A-73A. 2007
  • Further investigation of the role of factor XIII in priapism associated with SCD.  Blood. 998A-998A. 2007
  • Genomic complexity identifies patients with agressive chronic lymphocytic leukemia..  Blood. 151A-151A. 2007
  • Inhibition of nitric oxide synthase (NOS) 1, NOS2, and NOS3 enzymatic activities by vitamin B-12 and related corrins: Biochemical and molecular modeling studies.  Blood. 783A-783A. 2007
  • Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14 with differential expression of LATS2.  Blood. 617A-617A. 2007
  • MicroRNA expression in red blood cells from patients with PNH.  Blood. 1073A-1073A. 2007
  • Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.  Blood. 597A-598A. 2007
  • Sickle RBCs stimulate human monocyte cytokine expression.  Blood. 668A-669A. 2007
  • Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-incluced mobilization.  Blood. 72A-72A. 2007
  • The relationship of opiate analgesia to quality of life in an adult sickle cell population.  Blood. 670A-670A. 2007
  • Changes in the pattern of cytogenetic aberrations with advancing age in acute myeloid (Non-APL) leukemia: A Southwest Oncology study (S9007)..  Blood. 242A-242A. 2006
  • Coagulopathy from severe postpartum hemorrhage..  Blood. 116B-116B. 2006
  • Current prevalence of specific clinical outcomes in adult patients with HbSS or Hb S beta(0) thalassemia..  Blood. 353A-353A. 2006
  • Defects in E2F1/2 expression are associated with abnormalities in cell cycle and differentiation in EKLF-deficient erythroid cells..  Blood. 29A-29A. 2006
  • Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial..  Blood. 17A-18A. 2006
  • Determinants of PF4/heparin immunogenicity in a murine model of HIT..  Blood. 32A-33A. 2006
  • Effect of single dose in vivo propranolol therapy on in vitro adhesion of human SS RBC..  Blood. 363A-363A. 2006
  • Impaired maturation and survival of T lymphocytes, B lymphocytes, and NK cells in mice lacking Gimap5/Ian5..  Blood. 276A-276A. 2006
  • Interaction of activated sickle red cell LW with leukocytes induces leukocyte adhesion to endothelium via CD44-E-selectin..  Blood. 361A-361A. 2006
  • MK-0457, a novel multikinase inhibitor, has activity in refractory AML, including transformed JAK2 positive myeloproliferative disease (MPD), and in Philadelphia-positive ALL..  Blood. 556A-557A. 2006
  • Mechanism of soluble laminin-mediated enhancement of sickle red cell adhesion to endothelial cells..  Blood. 364A-364A. 2006
  • Preliminary results from the surveillance, epidemiology & risk factors for TTP (SERF-TTP) group: A prospective case-control study of idiopathic TTP..  Blood. 316A-317A. 2006
  • Prospective validation of a predictive model for early anemia in patients receiving cancer chemotherapy..  Blood. 140A-140A. 2006
  • Restoring initial thrombin generation does not normalize cutaneous wound healingin hemophilia B..  Blood. 306A-306A. 2006
  • Role of erythropoietin as an angiogenic factor and target in cancer..  Blood. 127A-127A. 2006
  • Unrelated donor hematopoietic stem cell transplantation (HSCT) in children with acute leukemia: Risks and benefits of umbilical cord blood (CB) versus HLAA, B, C, DRB1 allele-matched bone marrow (BM)..  Blood. 133A-133A. 2006
  • A differentiation block in erythroid cells lacking erythroid krupple-like factor (EKLF)..  Blood. 157A-157A. 2005
  • A phase 2 clinical trial of AP23573, an mTOR inhibitor, In patients with relapsed or refractory hematologic malignancies.  Blood. 835A-836A. 2005
  • A prospective study of bortezomib in combination with melphalan and prednisone for patients with previously untreated multiple myeloma..  Blood. 379B-379B. 2005
  • A randomized, open-label study of Lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition..  Blood. 121A-121A. 2005
  • A report of the event free survival (EFS) for children with newly diagnosed standard risk acute lymphoblastic leukemia (ALL) treated on pediatric oncology group (POG) protocol 9605..  Blood. 257A-257A. 2005
  • A report of the event-free survival (EFS) and neurotoxicity for children with newly diagnosed standard risk acute lymphoblastic leukemia (ALL) on pediatric oncology group (POG) protocol 9405..  Blood. 259A-259A. 2005
  • A single cell analysis of immunoglobulin genes in chronic lymphocytic leukemia (CLL): Evidence of intraclonal diversification associated with progressive somatic mutations and progressive antigen drive in immunoglobulin heavy and light chains.  Blood. 346A-347A. 2005
  • ADAMTS13 levels support hypothesis of distinct mechanistic pathways for early versus late-onset of thienopyridine-associated thrombotic thrombocytopenic purpura (TTP)..  Blood. 22A-22A. 2005
  • Adhesive characteristics of hemoglobin SC red blood cells..  Blood. 23B-24B. 2005
  • Antigen-specific T lymphocyte function following unrelated cord blood transplantation (UCBT)..  Blood. 849A-849A. 2005
  • CD26 inhibition enhances allogeneic donor cell homing and engraftment after in utero bone marrow transplantation..  Blood. 371A-371A. 2005
  • Clinical and genetic profiles of the aging sickle cell patient..  Blood. 26A-26A. 2005
  • Defibrotide (DF) for the treatment of Veno-Occlusive Disease (VOD) and multi-system organ failure (MOF) post SCT: Analysis of response and survival according to degree and type of MOV..  Blood. 120A-120A. 2005
  • Delayed wound healing in hemophilia B mice..  Blood. 894A-894A. 2005
  • Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia (ALL) - Cancer and leukemia group B study 9511.  Blood. 519A-519A. 2005
  • Erythropoietin and erythropoietin receptor expression in early stage non-small cell lung cancer: Prognostic significance..  Blood. 145B-145B. 2005
  • Ex vivo expansion of umbilical cord blood T cells for adoptive immunotherapy..  Blood. 15A-15A. 2005
  • Gene expression patterns identify novel biologically relevant signaling and transcriptional pathways involved in terminal erythroid differentiation and polycythemia vera.  Blood. 984A-984A. 2005
  • Incident TTP: Plasmapheresis therapy-related complications are common..  Blood. 365A-365A. 2005
  • Induction of chronic lymphocytic leukemia (CLL) apoptosis by nitric oxide synthase (NOS) inhibitors: Drug efficacy correlates with lipid solubility and NOS1 dissociation constant..  Blood. 342B-343B. 2005
  • Left sided heart dysfunction in sickle cell disease: Echocardiographic and genetic studies..  Blood. 27A-27A. 2005
  • Morbidity and associated sudden death in sickle cell disease..  Blood. 661A-661A. 2005
  • Multimodal dose dense therapy for mantle cell lymphoma..  Blood. 463B-463B. 2005
  • Partially HLA matched, non-myeloablative allogeneic transplantation.  Blood. 812A-812A. 2005
  • Pathogenic role of surface platelet factor 4 complexes in heparin-induced thrombocytopenia: Diagnostic and therapeutic implications..  Blood. 21A-21A. 2005
  • Predictors of survival in CLL: Multivariate analyses reveal significant correlation with IgV(H) gene mutation status, clinical stage, and cellular CD38 (but not Zap-70) expression..  Blood. 334B-334B. 2005
  • Priapism in SCD: Clinical and genetic correlations..  Blood. 887A-887A. 2005
  • Rapid in vivo acquisition of effector Tc1 phenotype even before myeloid engraftment predicts opportunistic infections (OI) in unrelated cord blood transplant recipients..  Blood. 409A-409A. 2005
  • Reaction of fibrinogen with homocysteine thiolactone mimics the dysfibrinogenemia produced by hyperhomocysteinemia..  Blood. 44A-44A. 2005
  • Response rates using international working group (IWG) criteria in patients with myelodysplastic syndromes (MDS) treated with azacitidine..  Blood. 709A-709A. 2005
  • Role of LW and AKAP79 in beta-adrenergic receptor signaling-induced sickle red blood cell adhesion..  Blood. 889A-889A. 2005
  • Sodium orthovanadate (NaV) effects CD22 expression, intracellular signaling, and lymphomacidal activity of the HB22.7 anti-CD22 monoclonal antibody..  Blood. 428A-428A. 2005
  • The relationship of plasma laminin levels to anemia and the effect of soluble laminin on sickle red cell adhesion in SCD..  Blood. 657A-657A. 2005
  • Thrombotic and hemorrhagic events for patients on pediatric oncology group (POG) protocols 9201, 9605, 9406..  Blood. 258A-259A. 2005
  • Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin..  Blood. 164A-164A. 2005
  • CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL..  Blood. 682A-682A. 2004
  • Characterization of autoantibodies to PF4/heparin in a rat model of cardiopulmonary bypass..  Blood. 825A-825A. 2004
  • Cord blood (CB) bank log CD34(+) and CD34(+) subsets (CD38(-)CD61(+)CD90(+)) are significantly correlated to log total CFU, CFU-GEMM, CFU-GM and BFU-E: A report from the COBLT program.  Blood. 119A-119A. 2004
  • Dose dense, high intensity therapy in newly diagnosed elderly patients with acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg (TM)) and high dose cytarabine (HiDAC)..  Blood. 212B-213B. 2004
  • Ex vivo gene therapy of a preadolescent with x-linked severe combined immunodeficiency.  Blood. 120A-120A. 2004
  • Gemtuzumab ozogamicin (Mylotarg (R)) as primary induction therapy for elderly patients with acute myeloid leukemia: A phase II trial.  Blood. 210B-210B. 2004
  • Heparin-induced thrombocytopenia is a thymus (T cell) dependent disorder..  Blood. 825A-825A. 2004
  • Human memory T cells proliferate but do not elicit cytotoxicity in response to alloantigens..  Blood. 347A-347A. 2004
  • Pharmacogenetics of minimal residual disease response in children with acute lymphoblastic leukemia (ALL)..  Blood. 132A-132A. 2004
  • Promotion of stem cell-derived new T cell generation by CD62L-memory T cells requires alloantigen recognition..  Blood. 831A-831A. 2004
  • Recryopreserved and rethawed aliquots with anti-CD3, IL-2, IL12 significantly expands NKT cells, NKT KIR substes and NK cytotoxicity compared to short-term expansion: Potential for CB adoptive cellular immunotherapy (ACI)..  Blood. 778A-778A. 2004
  • The use of DT388-IL3 fusion protein in patients with refractory acute myeloid leukemia(AML).  Blood. 212B-212B. 2004
  • A cost-effectiveness evaluation of imatinib versus interferon-alpha plus low-dose Ara-C for first-line treatment of patients with newly diagnosed chronic myeloid leukemia in the chronic phase..  Blood. 252A-252A. 2003
  • A novel method for ex-vivo expansion of NKCD3-/CD16+/56(+bright/dim) subjects expressing increased inhibitory receptors from cryopreserved/thawed/expanded/recryopreserved (CTECT) umbilical cord blood (UCB) using anti-CD3, IL-2, IL-7, and IL-12 (AB/CY): Implications for adoptive cellular immunotherapy (ACI) post umbilical cord blood transplantation (UCBT).  Blood. 963A-964A. 2003
  • A single cell analysis of immunoglobulin genes in chronic lymphocytic leukemia (CLL): Progressive somatic mutations in the immunoglobulin heavy and light chains contribute to intraclonal diversification in CLL..  Blood. 666A-666A. 2003
  • Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study..  Blood. 226A-226A. 2003
  • B-CAM/LU polymorphisms: Effect on sickle cell disease outcomes and cell adhesion..  Blood. 28B-28B. 2003
  • Bronchiolitis obliterans organizing pneumonia (BOOP) after bone marrow transplantation (BMT) for sickle cell disease (SCD): Association with acute chest syndrome (ACS)..  Blood. 460B-461B. 2003
  • Characterization of neuronal/glial differentiation of murine adipose-derived adult stromal cells..  Blood. 180B-180B. 2003
  • Chronic lymphocytic leukemia cells (CLL) express the neuronal isoform of nitric oxide synthase (NOS1), and NOS1-specific inhibitors induce CLL cell death..  Blood. 353B-353B. 2003
  • Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy from HLA matched siblings..  Blood. 238A-239A. 2003
  • Clinical outcome and immune reconstitution following alemtuzumab T cell depleted nonmyeloablative allogeneic immunotherapy using HLA mis-matched (3-5/6) related hematopoietic stem cells..  Blood. 482A-482A. 2003
  • Clopidogrel-associated TTP: Comparison of quality and timeliness of case reports obtained from the FDA, the pharmaceutical supplier, and from active pharmacovigilance..  Blood. 496A-497A. 2003
  • Clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): Clinical characteristics and predictors of survival..  Blood. 539A-539A. 2003
  • Combined infusion of peripheral blood stem cells (PBSC) plus bone marrow (BM) in poorly mobilizing patients undergoing high-dose therapy (HDT) and autologous stem cell transplant (ASCT).  Blood. 988A-989A. 2003
  • Complement-mediated hemolysis of erythrocytes is blocked by RNA aptamers to complement components C5 and C8..  Blood. 510A-510A. 2003
  • Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study..  Blood. 193A-193A. 2003
  • Dose-intense cyclophosphamide and etoposide for patients with refractory or high risk non-Hogdkin's lymphoma..  Blood. 287B-287B. 2003
  • Ex vivo expansion of umbilical cord blood (UCB) derived immature and mature T cells..  Blood. 965A-965A. 2003
  • Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease..  Blood. 29B-29B. 2003
  • Hematopoietic stem cell dose correlates with the speed of immune reconstitution after stem cell transplantation..  Blood. 396B-396B. 2003
  • In vitro exposure to epinephrine causes in vivo adhesion of human sickle red blood cells to vascular endothelium in nude mice: A new model for studying vaso-occlusion..  Blood. 261A-261A. 2003
  • Incidence, characteristics, and treatment of DVT in pregnant and postpartum women from the DVT FREE registry..  Blood. 808A-808A. 2003
  • Isolation of oligodendrocyte precursors from umbilical cord blood..  Blood. 965A-966A. 2003
  • Low-dose weekly paclitaxel for relapsed or refractory aggressive non-Hodgkins lymphoma..  Blood. 641A-641A. 2003
  • One day preparative regimen for allogeneic non-myeloablative stem cell transplantation (NMSCT) using 3-5/6 HLA matched related donors..  Blood. 476B-477B. 2003
  • Outcomes of 138 adult and pediatric patients undergoing cord blood transplantation from large cord blood bank..  Blood. 479A-479A. 2003
  • Pharmacokinetics of subcutaneous alemtuzumab in a patient with myeloma..  Blood. 385B-385B. 2003
  • Phase I trial with pharmocokinetics, dosimetry, toxicity and response of anti-stromal therapy using I-131 labeled chimeric anti-tenascin therapy for lymphoma..  Blood. 635A-636A. 2003
  • Phase one evaluation of gemcitabine, fludarabine, and mitoxantrone for relapsed or refractory leukemia..  Blood. 250B-250B. 2003
  • Platelet transmission electron microscopy in genetically confirmed MYH9-related disorders..  Blood. 788A-789A. 2003
  • Platelets stimulated with convulxin plus thrombin develop platelet subpopulations with increased binding of factor VIII, factor IX, and factor X..  Blood. 293A-293A. 2003
  • Preliminary results of unrelated umbilical cord blood transplantation for Sanfilippo syndrome (MPS III)..  Blood. 481A-481A. 2003
  • Protein phosphatase inhibitors as potent cytotoxic agents for B-cell CLL in vitro..  Blood. 360B-360B. 2003
  • Results of the cord blood transplantation study (COBLT) unrelated donor banking program from donor screening to characterization of banked units..  Blood. 461A-461A. 2003
  • Risk assessment for hepatic veno-occlusive disease in patients treated with gemtuzumab ozogamicin (Mylotarg (R)) with or without hematopoietic stem cell transplantation..  Blood. 871A-871A. 2003
  • Sickle RBCs form microaggregates in autologous plasma following epinephrine stimulation: A role for endogenous, soluble laminin..  Blood. 82A-82A. 2003
  • Splenectomy prior to umbilical cord blood (UCB) transplantation facilitates hematologic engraftment in pediatric and adult patients..  Blood. 470A-471A. 2003
  • Successful treatment of pure red cell aplasia (PRCA) with alemtuzumab (CAMPATH-1H)..  Blood. 19B-19B. 2003
  • TEPA augments the ex-vivo and in-vivo potential of cord blood derived CD34+cells: From basic science to clinical trials..  Blood. 961A-961A. 2003
  • The interaction of platelets and endothelial cells modulates the procoagulant/anticoagulant balance in heparin-induced thrombocytopenia..  Blood. 805A-805A. 2003
  • The small GTPase rapl activates BCAM/LU-dependent but not alpha 4 beta l-dependent adhesion in sickle red blood cells: Evidence for divergent adhesive pathways..  Blood. 82A-82A. 2003
  • Thrombocytopenia is common among patients treated with heparin and is rarely detected and evaluated with serologic testing and hematology consultation: Preliminary findings from the CATCH registry..  Blood. 537A-537A. 2003
  • Umbilical cord blood cells engraft and differentiate in cardiac tissues after human transplantation..  Blood. 153B-153B. 2003
  • Unrelated donor umbilical cord blood transplantation for X-linked adrenoleukodystrophy..  Blood. 479B-479B. 2003
  • cAMP-dependent activation of sickle red blood cell adhesion is associated with LW serine and tyrosine phosphorylation..  Blood. 263A-263A. 2003
  • Ability of minority patients to find donors from an ethnically diverse cord blood bank..  Blood. 640A-641A. 2002
  • Anti-CD3/IL-2/IL-7/IL-12 ex-vivo expansion of previously cryopreserved and subsequent recryopreservation of umbilical cord blood (UCB) cytotoxic T lymphocytes: A new procedure for adoptive cellular immunotherapy (ACI) post UCB transplant (T)..  Blood. 58A-58A. 2002
  • B-CAM/LU mediates laminin-independent cell-cell adhesion under both static and flow conditions..  Blood. 451A-451A. 2002
  • Campath-1H, T cell depleted nonmyeloablative peripheral blood stem cell transplantation from 3-6/6 HLA matched family members..  Blood. 638A-638A. 2002
  • Chronic lymphocytic leukemia (CLL) cell CD38 expression and inducible nitric oxide synthase (NOS2) expression are associated with serum IL-4 levels..  Blood. 357B-357B. 2002
  • Clinical evaluation of retroviral vectors for corrective gene transfer of adenosine deaminase (ADA) deficiency..  Blood. 116A-116A. 2002
  • Correction of congenital immunodeficiency disease with umbilical cord blood transplantation..  Blood. 858A-858A. 2002
  • Defibrotide (DF) appears effective and safe in a phase II, randomized study of patients (pts) with severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT)..  Blood. 112A-112A. 2002
  • Donor chimerism after T-Cell depleted (TCD)-Non-Myeloablative allogeneic SCT (NST) in hemoglobinopathies..  Blood. 401B-402B. 2002
  • Donor-specific tolerance after hematopoietic reconstitution with Campath-1H treated mobilized peripheral blood cells in a sublethal preconditioning regimen..  Blood. 410A-410A. 2002
  • Early T cell reconstitution along with graft and patient characteristics impact on opportunistic infections following unrelated cord blood transplantation in children..  Blood. 841A-841A. 2002
  • Elevated expression of numerous interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis..  Blood. 584A-584A. 2002
  • Ex vivo expansion of CB derived AC 133 progenitor cells with a polyamine copper chelator: Pre-clinical data..  Blood. 419B-419B. 2002
  • Ex vivo propagation and expansion of umbilical cord blood derived immature and mature T-cells..  Blood. 833A-833A. 2002
  • Failure of a minimally toxic non-myeloablative regimen to establish stable donor engraftment after transplantation for sickle cell anemia and beta-thalassemia..  Blood. 46A-46A. 2002
  • Fatal rapidly progressive liver disease associated to a novel mutation of the perforin gene..  Blood. 466A-466A. 2002
  • Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin..  Blood. 339A-339A. 2002
  • Gene expression profiling of AAV serotype 1-5 vectors in adult and neonatal animals using in vivo bioluminescence imaging..  Blood. 220A-220A. 2002
  • Immunological and clinical responses in patients with metastatic renal cell carcinoma to vaccination with tumor RNA transfected dendritic cells..  Blood. 867A-867A. 2002
  • Immunophenotypic and functional characterization of CD4+ CD25+ regulatory T cells as a function of aging in normal human peripheral blood and autoimmune disease..  Blood. 250A-250A. 2002
  • In vitro priming and generation of cytomegalovirus-specific T cell responses from umbilical cord blood..  Blood. 54B-55B. 2002
  • In vivo engraftment and differentiation of murine adipose derived stromal cells..  Blood. 731A-731A. 2002
  • Intracellular inositol polyphosphatides signaling via factor VIIa and factor X: The possible role of protease-activated receptor 2 and tissue factor activation..  Blood. 69B-69B. 2002
  • Modulation by epinephrine of PKA-dependent signaling pathways in sickle red blood cells induces activation of LW binding to endothelial cell alpha v beta 3 integrin..  Blood. 118A-118A. 2002
  • Morpholino antisense oligomer to integrin alpha, inhibits angiogenesis in a mouse model of retinopathy of prematurity..  Blood. 680A-680A. 2002
  • Nucleated cell count and CD34+count similar between cord blood units collected from Caucasian and non Caucasian umbilical cord blood donors..  Blood. 618A-618A. 2002
  • Philadelphia-chromosome (Ph+) acute lymphoblastic leukemia (ALL) in children and adolescents: Outcome with unrelated placental cord blood (PCB) transplantation..  Blood. 856A-856A. 2002
  • Preliminary analysis of a randomized phase 2 study of the safety and efficacy of 1 vs. 2 doses of gemtuzumab ozogamicin (Mylotarg (R)) in patients with high risk myelodysplastic syndrome..  Blood. 795A-795A. 2002
  • Racial/ethnic diversity achieved in national network of cord blood banks..  Blood. 186A-186A. 2002
  • Relationship of sickle red blood cell laminin binding to disease activity..  Blood. 450A-451A. 2002
  • Successful treatment of lymphoma xenografts with the anti-CD22 mAb HB22.7 alone and augmented response when given with Y90-DOTA-PEPTIDE-LYM-1 that is sequence specific..  Blood. 315B-315B. 2002
  • Three methods of T-cell depletion of HPCT products: Analysis of CD34+ cell and lymphocyte purity and recovery..  Blood. 835A-836A. 2002
  • Treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy (HDIT) and autologous stem cell transplantation (SCT): 2 year follow-up..  Blood. 864A-864A. 2002
  • Treatment of severe systemic sclerosis with allogenic marrow transplantation..  Blood. 460B-461B. 2002
  • Unrelated umbilical cord blood (UCB) transplantation for infants with acute lymphoblastic leukemia (ALL) and rearrangements of the 11q23 chromosomal region..  Blood. 855A-856A. 2002
  • Unrelated umbilical cord blood transplant for Wiskott-Aldrich syndrome..  Blood. 855A-855A. 2002
  • Updated results of bone marrow transplantation (BMT) for sickle cell disease (SCD): Impact on CNS disease..  Blood. 45A-46A. 2002
  • Effect of hyperhomocysteinemia on protein C activation and activity in vivo..  Blood. 257A-258A. 2001
  • Enumerating functionally mature monocyte-derived dendritic cells for use in cancer immunotherapy..  Blood. 851A-851A. 2001
  • High dose factor VIIa enhances clot stability in a model of hemophilia..  Blood. 826A-827A. 2001
  • Quantitating antigen specific T cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot and intracellular cytokine analysis..  Blood. 23A-23A. 2001
  • Addition of stem cells from allogeneic donors accelerates engraftment and immune reconstitution after stem cell transplantation..  Blood. 172A-172A. 2000
  • Dendritic cell (DC) reconstitution after non-myeloablative allogeneic stem cell transplants..  Blood. 305B-305B. 2000
  • Hematopoiteic stem cell doses correlate with the speed of immune reconstitution after allogeneic stem cell transplantation..  Blood. 772A-772A. 2000
  • Hyperhomocysteinemia induces alterations in fibrinogen function and fibrin clot structure in a rabbit model..  Blood. 39A-39A. 2000
  • Hyperhomocysteinemia induces monocyte tissue factor (TF) expression in vivo..  Blood. 32B-32B. 2000
  • Multiple signals are required for IL-12 production by Flt-3 ligand mobilized dendritic cells..  Blood. 295A-295A. 2000
  • Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg (TM), CMA-676) followed by hematopoietic stem cell transplantation..  Blood. 320A-320A. 2000
  • V beta repertoire of T lymphocytes emerging in adults after unrelated umbilical cord blood (UCB) allogeneic transplantation..  Blood. 788A-788A. 2000
  • Activated protein C (APC) functions by inhibiting initiation of coagulation rather than by terminating a hemostatic response..  Blood. 224A-224A. 1999
  • De-encryption of cellular tissue factor is independent of its cytoplasmic domain..  Blood. 227A-227A. 1999
  • Efficacy and safety of CMA-676 in patients with AML in first relapse..  Blood. 696A-696A. 1999
  • FLT3-ligand (FLT3L) mobilization of dendritic cells (DC) in patients with metastatic colon cancer..  Blood. 48A-48A. 1999
  • Impaired immune function in murine adult cord blood recipients..  Blood. 568A-568A. 1999
  • Reconstitution of the immunohematopoietic system in adult murine recipients across major histocompatibility complex by near-term fetal blood..  Blood. 321A-321A. 1999
  • Residual trisomic cells in a patient with resolving transient myeloproliferative disorder and trisomy 21 mosaicism..  Blood. 291B-291B. 1999
  • The initial rate, but not the total amount, of thrombin (IIa) generated determines fibrin clot structure in a cell-based model of coagulation..  Blood. 230A-231A. 1999
  • Tissue factor independent effect of high dose factor VIIa directly correlates with factor X levels..  Blood. 228A-228A. 1999